Syngene International Limited

Rs 1,037

to globally recognized standards for clinical research and data quality Revenue from Operations Rs 1,037 Cr ( 2% Y-o-Y) ~USD 112 Mn Operating EBITDA margin 29% (34% in Q4 FY25) PAT before exceptional it

2%

ecognized standards for clinical research and data quality Revenue from Operations Rs 1,037 Cr ( 2% Y-o-Y) ~USD 112 Mn Operating EBITDA margin 29% (34% in Q4 FY25) PAT before exceptional items : R

29%

ata quality Revenue from Operations Rs 1,037 Cr ( 2% Y-o-Y) ~USD 112 Mn Operating EBITDA margin 29% (34% in Q4 FY25) PAT before exceptional items : Rs. 153 Cr (-16%YoY) ▪ Sustainability & ESG: Incl

34%

uality Revenue from Operations Rs 1,037 Cr ( 2% Y-o-Y) ~USD 112 Mn Operating EBITDA margin 29% (34% in Q4 FY25) PAT before exceptional items : Rs. 153 Cr (-16%YoY) ▪ Sustainability & ESG: Included

Rs. 153

% Y-o-Y) ~USD 112 Mn Operating EBITDA margin 29% (34% in Q4 FY25) PAT before exceptional items : Rs. 153 Cr (-16%YoY) ▪ Sustainability & ESG: Included in the S&P Global Sustainability Yearbook 2026, ranki

16%

112 Mn Operating EBITDA margin 29% (34% in Q4 FY25) PAT before exceptional items : Rs. 153 Cr (-16%YoY) ▪ Sustainability & ESG: Included in the S&P Global Sustainability Yearbook 2026, ranking in th

9%

the S&P Global Sustainability Yearbook 2026, ranking in the top 10 life sciences companies and top 9% globally; also recognised as an ‘Industry Mover’ for the highest year-on-year improvement in its C

Rs 3,739

to Executive Chairperson, effective 1 April 2026, for a five-year term Revenue from Operations Rs 3,739 Cr ( 3% Y-o-Y) ~USD 419 Mn Operating EBITDA margin 25% (29% in FY25) - Siddharth Mittal appointed

3%

Chairperson, effective 1 April 2026, for a five-year term Revenue from Operations Rs 3,739 Cr ( 3% Y-o-Y) ~USD 419 Mn Operating EBITDA margin 25% (29% in FY25) - Siddharth Mittal appointed Managi

25%

e-year term Revenue from Operations Rs 3,739 Cr ( 3% Y-o-Y) ~USD 419 Mn Operating EBITDA margin 25% (29% in FY25) - Siddharth Mittal appointed Managing Director & Chief Executive Officer, effective

Rs. 380

ective 1 May 2026; both previously held leadership roles at Biocon PAT before exceptional items : Rs. 380 Cr ( -20% YoY) Putting Science to Work 5 2 Syngene – Putting Science to Work Partner in innovat

20%

026; both previously held leadership roles at Biocon PAT before exceptional items : Rs. 380 Cr ( -20% YoY) Putting Science to Work 5 2 Syngene – Putting Science to Work Partner in innovation: #Put

Integrated services

1

IR Contact

1

Media Contact

1

Integrated services

• • • Manufacturing Research Services Development and for small/large molecules • • • • Product Based Biosimilars Formulations and Compounds Alternative Therapeutic Drugs Putting Science to Work 29 Shareholding and Share Information Syngene’s shareholders* 1% 47% Promoter & Promoter Group 53% Public ESOP Trust Syngene’s Share Information* NSE Ticker BSE Ticker Market Cap (Rs. Mn) % free-float^ Free-float market cap (Rs. Mn) Share Outstanding (Mn) SYNGENE 539268 1,57,106 47% 74,337 403 • As on 31st March 2026 • ^ Free float includes shares held by public and in ESOP Trust Putting Science to Work 30 For more details Visit our website www.syngeneintl.com https://www.linkedin.com/company/syngene-international-limited https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ